Intuniv (guanfacine XR) / Shionogi, Takeda 
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Intuniv (guanfacine XR) / Shionogi, Takeda
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
NCT05870605: Drug Use Study With Intuniv® in European Countries

Completed
N/A
5000
Europe
No Intervention
Shire
Attention Deficit Hyperactivity Disorder (ADHD)
04/22
04/22
AGUALIS, NCT03333668: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

Active, not recruiting
N/A
20
Europe
Lisdexamfetamine dimesylate, Vyvanse (Shire Pharmaceuticals Ltd.), Guanfacine Extended Release Oral Tablet, Intuniv (Shire Pharmaceuticals Ltd.), Placebo
King's College London, Shire
ADHD
12/22
03/25

Download Options